(MENAFN- PR Newswire)
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- The global
prefilled syringes market
size is estimated to grow by USD 4.04 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost
9.45% during the forecast period. Favorable regulations and guidelines
is driving market growth,
with a trend towards
increasing number of approval of biologics. However,
competition from alternative drug delivery systems poses a challenge. Key market players include Ajinomoto Bio Pharma Services, ApiJect Systems Corp., AptarGroup Inc., Baxter International Inc., Becton Dickinson and Co., Catalent Inc., Fresenius SE and Co. KGaA, Gerresheimer AG, Haselmeier GmbH, Nipro Corp., Novartis AG, Owen Mumford Ltd., Recipharm AB, SCHOTT AG, SHL Medical AG, STERINOVA, Terumo Corp., Vetter Pharma Fertigung GmbH and Co. KG, Viatris Inc., and West Pharmaceutical Services Inc..
Continue Reading
Technavio has announced its latest market research report titled Global prefilled syringes market 2024-2028
Get a detailed analysis on regions, market segments, customer landscape, and companies-
View the snapshot of this report
| Prefilled Syringes Market Scope |
| Report Coverage |
Details |
| Base year |
2023 |
| Historic period |
2018 - 2022 |
| Forecast period |
2024-2028 |
| Growth momentum & CAGR |
Accelerate at a CAGR of 9.45% |
| Market growth 2024-2028 |
USD 4045.9 million |
| Market structure |
Fragmented |
| YoY growth 2022-2023 (%) |
8.42 |
| Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution |
North America at 37% |
| Key countries |
US, Canada, Germany, China, and UK |
| Key companies profiled |
Ajinomoto Bio Pharma Services, ApiJect Systems Corp., AptarGroup Inc., Baxter International Inc., Becton Dickinson and Co., Catalent Inc., Fresenius SE and Co. KGaA, Gerresheimer AG, Haselmeier GmbH, Nipro Corp., Novartis AG, Owen Mumford Ltd., Recipharm AB, SCHOTT AG, SHL Medical AG, STERINOVA, Terumo Corp., Vetter Pharma Fertigung GmbH and Co. KG, Viatris Inc., and West Pharmaceutical Services Inc. |
Market Driver
The pharmaceutical industry's shift from small-molecule chemical drugs to large-molecule biologics has led to significant advancements in treating chronic diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis. In 2022, the FDA approved 37 new drugs and 15 biologics. Pre-filled syringes offer advantages like material and cost savings, accuracy, and ease of administration, making them an ideal choice for packaging and delivering biological products. Of the top ten drugs in pre-filled syringes, nine are biologics. Over 1,000 biologics and medicines are in clinical development, and most are expected to use pre-filled syringes as their primary container, creating opportunities for the global pre-filled syringes market. (Exact word count: 96)
The prefilled syringes market is experiencing significant growth due to the increasing demand for convenient and precise administration of parenteral medications, particularly in emergency situations such as anaphylactic shock. Pen injectors and safety syringes are popular choices for patients and healthcare providers, reducing the risk of needlestick injuries. However, the market faces challenges like dose precision, risk of contamination, and drug wastage. The trend towards biologics, biosimilars, insulin, and mRNA COVID-19 vaccines is driving the market, with home care services and hospital pharmacies being major consumers. The market also caters to chronic diseases like heart diseases, diabetes, and autoimmune diseases. The assumption that prefilled syringes are more expensive than conventional vials may not always be true, considering the global healthcare costs and potential product recalls. The target population includes patients and healthcare professionals, with a focus on biologics and biosimilars. The market also addresses the needs of various disease populations, including diabetes prevalence and cancer cases. Lubrication technology, multi-chamber syringes, and flush syringes are key trends in the market.
Discover 360° analysis of this market. For complete information, schedule your consultation -
Book Here!
Market
Challenges
The pre-filled syringes market encounters significant competition from alternative drug delivery systems, including
microneedles, wearable and connected delivery devices, and nano patches. These non-invasive options offer easier use, painless delivery, and controlled drug release. However, pre-filled syringes are not entirely pain-free. Emerging technologies, such as Unilife's and BD's wearable injector devices, provide customizable dosages for biologics, vaccines, and small molecules. Microneedles, an upcoming technology, is expected to dominate vaccination programs, with products like Soluvia by BD and MicronJet600 by NanoPass Technologies already marketed. Companies like 3M, Corium International, Zosano Pharma, BD, NanoPass Technologies, and LTS Lohmann Therapie-Systeme AG invest heavily in microneedle drug delivery systems for insulin, vaccines, and local anesthetics. Nanopatches offer similar immune protection using 100 times less vaccine and lower manufacturing costs. These alternatives are expected to capture a substantial market share, potentially hindering the growth of pre-filled syringes during the forecast period.
The
prefilled syringes market faces several challenges in catering to the growing demand from chronic disease patients, including heart diseases, diabetes, and autoimmune disorders. Needlestick legislations necessitate safety features, increasing syringe costs. Biologics and biosimilars require larger syringe volumes, challenging assumptions about target disease population size. Chronic diseases like diabetes have large prevalence rates, with an estimated 463 million diabetes cases and 19.3 million cancer cases worldwide. Needle stick injuries and contaminated needles pose risks for patients and healthcare professionals. Insufficient healthcare funding and medical inflation create funding gaps, driving the search for cheaper alternatives like disposable syringes or oral drug delivery methods. Safety prefilled syringes, self injection devices, and autoinjectors are popular solutions for geriatric patients and those requiring biological therapies. However, challenges remain in optimizing API use, reducing drug waste, and analyzing partnerships for self administering devices. The annual cost burden and patient compliance are critical factors in treatment regimens, making safety and affordability key considerations for the prefilled syringes market.
For more insights on driver and challenges
-
Request a
sample report!
Segment Overview
This prefilled syringes market report extensively covers market segmentation by
Material
1.1 Glass pre-filled syringes
1.2 Plastic pre-filled syringes
Type
2.1 Disposable
2.2 Reusable
Geography
3.1 North America
3.2 Europe
3.3 Asia
3.4 Rest of World (ROW)
1.1 Glass pre-filled syringes- The global prefilled syringes market is anticipated to experience notable growth, with glass pre-filled syringes playing a significant role. These syringes, which come pre-packaged with drugs or biologicals, offer several advantages. Their widespread acceptance among end-users and regulatory ease make them an attractive option. Glass pre-filled syringes are the industry standard due to their long-standing popularity and suitability for parenteral drugs. However, they have drawbacks, such as fragility, potential interaction with biological drugs, and the risk of delamination and plunger failure. Despite these challenges, glass pre-filled syringes offer benefits like minimizing pharmaceutical waste, environmental advantages, improved safety, and ease of use. Leading vendors, such as Baxter, provide a range of glass pre-filled syringes and product enhancements, ensuring market growth in this segment during the forecast period.
For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report
Learn and explore more about Technavio's in-depth research reports
The global Amyotrophic Lateral Sclerosis (ALS) treatment market is witnessing significant growth, driven by advancements in research and emerging therapies. The market is projected to expand due to increasing ALS prevalence, rising awareness, and innovative treatment approaches. Key players are focusing on developing novel drugs and therapies, including gene therapies and disease-modifying treatments. North America leads the market, owing to strong healthcare infrastructure and high research investments. However, challenges such as high treatment costs and complex regulatory requirements persist. The market's future looks promising with continued innovation and investment.
Research Analysis
Prefilled syringes have gained significant attention in the healthcare industry due to their convenience and safety advantages over conventional vials. The market for prefilled syringes is expected to grow substantially in the coming years, driven by the increasing prevalence of chronic diseases such as heart diseases, autoimmune disorders like rheumatoid arthritis, and oncological disorders. The need for needlestick legislations to minimize the risk of infections among patients and healthcare professionals is another key factor. Prefilled syringes are increasingly being used for injectable medications, including biologics and biosimilars, insulin, and the mRNA COVID-19 vaccine.
Market Research Overview
Prefilled syringes have gained significant importance in the healthcare industry due to their convenience, safety, and precision in delivering dosages for chronic diseases such as heart diseases, diabetes, and autoimmune disorders. These conditions affect large target populations, with diabetes prevalence reaching over 460 million worldwide and cancer cases estimated to be around 19.3 million in 2020. Needlestick legislations aim to protect patients and healthcare professionals from needle stick injuries and blood-borne infections. Prefilled syringes offer safety features and reduce the risk of contamination and insufficient dosing. However, factors like insufficient healthcare funding, medical inflation, and funding gaps limit their widespread adoption. Cheaper alternatives like disposable syringes, oral drug delivery, inhalable insulin, and nasal drug delivery are also considered.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
Material
Glass Pre-filled Syringes
Plastic Pre-filled Syringes
Type
Geography
North America
Europe
Asia
Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:
[email protected]
Website:
SOURCE Technavio
MENAFN13082024003732001241ID1108551412
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.